Planning

PCR Molecular Testing

UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST

This public procurement record has 1 release in its history.

Planning

27 Jul 2022 at 08:19

Summary of the contracting process

The University Hospitals Birmingham NHS Foundation Trust is planning to tender for PCR Molecular Testing Platforms, focusing on providing rapid molecular testing for lung cancer samples. This initiative falls under the healthcare services industry, with a specific classification for pathology services. The procurement stage is currently at the planning phase, and a future notice is expected on 1st November 2022. The delivery of services is anticipated across the UK, aimed at enhancing diagnostic capabilities in cancer care.

This tender presents significant opportunities for businesses engaged in medical technology and diagnostic services, particularly those specialising in molecular testing equipment and systems. Companies that can provide highly sensitive and rapid testing solutions, especially for oncology applications, will be well-positioned to compete. The requirement for quick turnaround and adaptability in technology underscores the need for innovative solutions in the healthcare sector, creating potential for growth and collaboration with a leading NHS Trust.

Find more tenders on our Open Data Platform.
How relevant is this notice?

Notice Title

PCR Molecular Testing

Notice Description

University Hospitals Birmingham NHS Trust are looking at tendering for PCR Molecular Testing Platforms in order to carry out rapid molecular testing.

Lot Information

Lot 1

The Molecular Pathology Diagnostic Service (MPDS) at UHB needs to be able to deliver a quick and highly sensitive assessment of RET and MET alterations in lung cancer samples, which is required prior to the prescription of drugs targeting RET and MET. A quick turn around time is required, since lung cancer patients need to be started on the treatment as soon as possible. Lung tumour samples are of small size; there is therefore a need for a highly sensitive technology with a very low rate of failure. MPDS receives at least 350 lung cancer samples every month for MET exon 14 mutation and RET translocation testing; the numbers are likely to increase; the technology therefore needs to be adaptable to the needs. In order to take into account the various clinical circumstances, the technology needs to allow MPDS to perform RET and MET exon 14 alterations within a few hours for selected tumours.

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-03565e
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/020409-2022
Current Stage
Planning
All Stages
Planning

Procurement Classification

Notice Type
Planning Notice
Procurement Type
Standard
Procurement Category
Services
Procurement Method
Not Specified
Procurement Method Details
Not specified
Tender Suitability
Not specified
Awardee Scale
Not specified

Common Procurement Vocabulary (CPV)

CPV Divisions

85 - Health and social work services


CPV Codes

85111800 - Pathology services

Notice Value(s)

Tender Value
Not specified
Lots Value
Not specified
Awards Value
Not specified
Contracts Value
Not specified

Notice Dates

Publication Date
27 Jul 20223 years ago
Submission Deadline
Not specified
Future Notice Date
1 Nov 2022Expired
Award Date
Not specified
Contract Period
Not specified - Not specified
Recurrence
Not specified

Notice Status

Tender Status
Planned
Lots Status
Planned
Awards Status
Not Specified
Contracts Status
Not Specified

Contracting Authority (Buyer)

Main Buyer
UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
BIRMINGHAM
Postcode
B15 1NU
Post Town
Birmingham
Country
England

Major Region (ITL 1)
TLG West Midlands (England)
Basic Region (ITL 2)
TLG3 West Midlands
Small Region (ITL 3)
TLG31 Birmingham
Delivery Location
Not specified

Local Authority
Birmingham
Electoral Ward
Edgbaston
Westminster Constituency
Birmingham Edgbaston

Further Information

Notice URLs

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

Download

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

{
    "tag": [
        "compiled"
    ],
    "id": "ocds-h6vhtk-03565e-2022-07-27T09:19:32+01:00",
    "date": "2022-07-27T09:19:32+01:00",
    "ocid": "ocds-h6vhtk-03565e",
    "description": "Due to Issues with the portal the PIN has been republished for an additional week.",
    "initiationType": "tender",
    "tender": {
        "id": "ocds-h6vhtk-03565e",
        "legalBasis": {
            "id": "32014L0024",
            "scheme": "CELEX"
        },
        "title": "PCR Molecular Testing",
        "status": "planned",
        "classification": {
            "scheme": "CPV",
            "id": "85111800",
            "description": "Pathology services"
        },
        "mainProcurementCategory": "services",
        "description": "University Hospitals Birmingham NHS Trust are looking at tendering for PCR Molecular Testing Platforms in order to carry out rapid molecular testing.",
        "lots": [
            {
                "id": "1",
                "description": "The Molecular Pathology Diagnostic Service (MPDS) at UHB needs to be able to deliver a quick and highly sensitive assessment of RET and MET alterations in lung cancer samples, which is required prior to the prescription of drugs targeting RET and MET. A quick turn around time is required, since lung cancer patients need to be started on the treatment as soon as possible. Lung tumour samples are of small size; there is therefore a need for a highly sensitive technology with a very low rate of failure. MPDS receives at least 350 lung cancer samples every month for MET exon 14 mutation and RET translocation testing; the numbers are likely to increase; the technology therefore needs to be adaptable to the needs. In order to take into account the various clinical circumstances, the technology needs to allow MPDS to perform RET and MET exon 14 alterations within a few hours for selected tumours.",
                "status": "planned"
            }
        ],
        "items": [
            {
                "id": "1",
                "additionalClassifications": [
                    {
                        "scheme": "CPV",
                        "id": "85111800",
                        "description": "Pathology services"
                    }
                ],
                "deliveryAddresses": [
                    {
                        "region": "UK"
                    }
                ],
                "relatedLot": "1"
            }
        ],
        "communication": {
            "futureNoticeDate": "2022-11-01T00:00:00Z"
        },
        "coveredBy": [
            "GPA"
        ]
    },
    "parties": [
        {
            "id": "GB-FTS-59931",
            "name": "University Hospitals Birmingham NHS Foundation Trust",
            "identifier": {
                "legalName": "University Hospitals Birmingham NHS Foundation Trust"
            },
            "address": {
                "streetAddress": "14-17 George Road",
                "locality": "Birmingham",
                "region": "UK",
                "postalCode": "B15 1NU",
                "countryName": "United Kingdom"
            },
            "contactPoint": {
                "name": "Leanne Wingrove",
                "telephone": "+44 1213712000",
                "email": "leanne.wingrove@uhb.nhs.uk"
            },
            "roles": [
                "buyer",
                "centralPurchasingBody"
            ],
            "details": {
                "url": "http://www.uhb.nhs.uk",
                "classifications": [
                    {
                        "scheme": "TED_CA_TYPE",
                        "id": "BODY_PUBLIC",
                        "description": "Body governed by public law"
                    },
                    {
                        "scheme": "COFOG",
                        "id": "07",
                        "description": "Health"
                    }
                ]
            }
        }
    ],
    "buyer": {
        "id": "GB-FTS-59931",
        "name": "University Hospitals Birmingham NHS Foundation Trust"
    },
    "language": "en"
}